Exemestane: all 119 studies that test it

Page 1 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen StudyRecruitingNCT07706374Phase 1
• Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingNCT07499999Phase 2
• Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)RecruitingNCT07395336Phase 2
• Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingNCT07369505Phase 1
• A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Phase 3
• A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingNCT06979596Phase 2
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3
• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
• Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingNCT06364267Phase 2
• Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingNCT06223698Phase 3
• Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationNCT05645536Phase 3
• Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2
• Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingNCT02476786Phase 2
• A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerTerminatedNCT06630325Phase 2Results posted
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Phase 3Results posted
• The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast CancerCompletedNCT04129216Phase 2Results posted
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial CancerCompletedNCT03300557Phase 2Results posted
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results posted
• Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast CancerCompletedNCT03219476Phase 2Results posted
• Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT03176238Phase 3Results posted
• GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerTerminatedNCT02983604Phase 1/2Results posted
• Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
• Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted
• Exemestane in Post-Menopausal Women With NSCLCCompletedNCT02666105Phase 2Results posted
• Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast CancerCompletedNCT02598557Phase 2Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerCompletedNCT02392611Phase 1Results posted
• ER Reactivation Therapy for Breast CancerCompletedNCT02188745Phase 2Results posted
• Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCompletedNCT02069093Phase 2Results posted
• Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedNCT02049957Phase 2Results posted
• Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results posted
• Exemestane and Cyclophosphamide for Metastatic Breast CancerCompletedNCT01963481Phase 2Results posted
• BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid TumorsCompletedNCT01938846Phase 1Results posted
• BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCompletedNCT01870505Phase 1Results posted
• Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 TumorsCompletedNCT01831076Phase 2Results posted
• An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCompletedNCT01743560Phase 4Results posted
• Exemestane-RAD001-MetforminTerminatedNCT01627067Phase 2Results posted
• Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results posted
• Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerCompletedNCT01385280Not applicableResults posted
• A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyCompletedNCT01381874Phase 2Results posted
• Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast CancerCompletedNCT01237327Phase 3Results posted
• Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedNCT01176916Phase 4Results posted
• Exemestane or Docetaxel-Cytoxan in Low Recurrence Score CancersCompletedNCT00941330Phase 2Results posted
• Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerTerminatedNCT00905021Phase 1/2Results posted
• Exemestane in Treating Postmenopausal Women With Stage IV Breast CancerCompletedNCT00810797Phase 2Results posted
• Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast CancerTerminatedNCT00793546Phase 2Results posted
• Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerCompletedNCT00767520Phase 2Results posted
• Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02CompletedNCT00659373Phase 3Results posted
• Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsCompletedNCT00432172Phase 2Results posted
• A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerTerminatedNCT00417885Phase 1/2Results posted
• Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast CancerCompletedNCT00265759Phase 3Results posted
• Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3Results posted
• Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00201864Phase 2Results posted
• Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast CancerCompletedNCT00201773Phase 2Results posted
• Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast CancerTerminatedNCT00194792Phase 2Results posted
• Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerCompletedNCT00143390Phase 3Results posted
• Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast CancerCompletedNCT00083174Phase 3Results posted
• Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast CancerCompletedNCT00073073Phase 2Results posted
• Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedNCT00066703Phase 3Results posted
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedNCT00066690Phase 3Results posted
• Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast CancerCompletedNCT00066573Phase 3Results posted
• Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerCompletedNCT00038467Phase 3Results posted
• Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On TamoxifenCompletedNCT00038103Phase 2Results posted
• Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneCompletedNCT00036270Phase 3Results posted
• Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsActive, not recruitingNCT06169124Phase 2
• Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerCompletedNCT05150652Phase 2
• Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsCompletedNCT04659551Phase 2
• Neoadjuvant Tucidinostat and Exemestane in Early Breast CancerCompletedNCT04465097Phase 2
• Exemestane in Hormone Receptor Positive High Grade Ovarian CancerTerminatedNCT04460807Phase 3
• Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedNCT03308201Phase 1
• Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast CancerWithdrawnNCT03238703Phase 4
• A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）Status unknownNCT03137368Phase 3
• A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03125746Phase 1
• Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer PatientsCompletedNCT02995772Phase 3
• Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedNCT02990845Phase 1/2
• Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast CancerCompletedNCT02820961Phase 1
• Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerCompletedNCT02676986Phase 2
• A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBCStatus unknownNCT02592746Phase 2
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
• Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
• Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneStatus unknownNCT02109913Not applicable
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
• Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerStatus unknownNCT02025712Phase 2
• Exemestane in Advanced and Recurrent Endometrial CarcinomaCompletedNCT01965080Phase 2
• Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung CancerCompletedNCT01664754Phase 1
• Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PDStatus unknownNCT01655004Not applicable
• Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast CancerStatus unknownNCT01648608Phase 2/3
• 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT01626222Phase 3
• Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast CancerCompletedNCT01612871Phase 4
• Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or NotCompletedNCT01553903Phase 4
• Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNCT01331447Not applicable
• Bioequivalency Study of Exemestane 25 mg Tablet Under Fed ConditionsCompletedNCT01331434Not applicable
• Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted ConditionsCompletedNCT01331421Not applicable
• 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerTerminatedNCT01303679Phase 3
• MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast CancerWithdrawnNCT01240928Phase 1
• ELBA: Exemestane and Lapatinib in Advanced Breast CancerWithdrawnNCT01005641Phase 2
• Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule FindingCompletedNCT01004081Phase 2
• Exemestane (Aromasine) + Tamoxifen - Breast Neo-AdjuvantCompletedNCT00919399Phase 2
• Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast CancerStatus unknownNCT00902954Phase 3
• Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast CancerCompletedNCT00893061Phase 3

← Exemestane overview